KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDNN2xsUUN3ME2zMlI4OzV{IN88US=> MmDyV2FPT0WU
HuO-3N1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfufIc5UUN3ME20MlE4OTR{IN88US=> M3XrenNCVkeHUh?=
LAMA-84 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz1TWM2OD12LkW4OFY2KM7:TR?= M2Lhd3NCVkeHUh?=
CAL-72 M2jwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWfGc5UUN3ME21MlQ5ODh2IN88US=> NV7MZWZ1W0GQR1XS
LoVo M3PNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TLeWlEPTB;Nj65N|I{QSEQvF2= NH3hRlNUSU6JRWK=
HH M4Pve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP6Xo1KSzVyPUiuNlc3PzFizszN M2TkV3NCVkeHUh?=
SK-MEL-3 NF;WNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXZcpVGUUN3ME24MlI5PTd3IN88US=> MV\TRW5ITVJ?
KM12 Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q2dGlEPTB;OT6yNVE1OiEQvF2= MX;TRW5ITVJ?
NCI-H1437 NEnPOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITmPIVKSzVyPUmuPFA6PyEQvF2= NXTzcmZDW0GQR1XS
NCI-H1838 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Ljb2lEPTB;MUGuNVg3PSEQvF2= MnvzV2FPT0WU
J-RT3-T3-5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXCS3NKSzVyPUGxMlI1OTdizszN MYfTRW5ITVJ?
GOTO M17oWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T6eGlEPTB;MUGuOlk6PiEQvF2= NFfk[GlUSU6JRWK=
LB2241-RCC MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknNTWM2OD1zMT63NVg3KM7:TR?= MV7TRW5ITVJ?
ES7 M4TPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLaXHl2UUN3ME2xNU44QDhizszN MYHTRW5ITVJ?
KP-N-YS M3Trfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfWTWM2OD1zMj62N|U1KM7:TR?= NVPHdJlRW0GQR1XS
CAL-12T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDXTWM2OD1zMz62NVch|ryP MUfTRW5ITVJ?
COLO-684 NYL3e2dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD1zND6xOVY6KM7:TR?= M2DrdHNCVkeHUh?=
DOK NWnVOI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PMNWlEPTB;MUWuN|MzQSEQvF2= MnPjV2FPT0WU
Hs-578-T NUL2NJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXnc2VKSzVyPUG1MlQyQDJizszN NXe3emhJW0GQR1XS
D-423MG NF\mXINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jSeGlEPTB;MUWuOVI{PiEQvF2= M4nVbnNCVkeHUh?=
DBTRG-05MG NV;qbGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLTWM2OD1zNT62NVEyKM7:TR?= M1f1SXNCVkeHUh?=
VM-CUB-1 NIHTdnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTyfoZKSzVyPUG1Mlk5PDlizszN NFP2dmZUSU6JRWK=
KG-1 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF4LkC5PVYh|ryP NELk[IVUSU6JRWK=
8305C NFL3TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnXW5Z[UUN3ME2xOk4yQDh7IN88US=> NIjEe|VUSU6JRWK=
HuH-7 MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDKRlZKSzVyPUG2MlI3PzRizszN NWHqdZd4W0GQR1XS
LXF-289 NHvGOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH1TWM2OD1zNj6yO|Q4KM7:TR?= M1[wN3NCVkeHUh?=
NCI-H1793 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF4LkS3NVIh|ryP NX;0[lI3W0GQR1XS
ChaGo-K-1 NHrpPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTF4Lk[1Olgh|ryP NHnaWGhUSU6JRWK=
GCIY MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXmRXVSUUN3ME2xOk44QTB3IN88US=> MVjTRW5ITVJ?
SK-MEL-28 NFrVdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX2S3JNUUN3ME2xO{4xPDd3IN88US=> MUDTRW5ITVJ?
NCI-SNU-1 NXG1bolyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF5LkGyOlkh|ryP MY\TRW5ITVJ?
CTB-1 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPVNnFKSzVyPUG3MlIzPTlizszN M1X3[XNCVkeHUh?=
NCI-H82 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD1zNz60OVc{KM7:TR?= MljDV2FPT0WU
HCC2998 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Kwb2lEPTB;MUeuOlc{OyEQvF2= M{nJenNCVkeHUh?=
NCI-H2030 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG1Z5FKSzVyPUG4MlE6QTdizszN NIO5No1USU6JRWK=
HuP-T3 NYrUUWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnCWndKSzVyPUG4MlU5QDhizszN MkLrV2FPT0WU
697 M{DxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnXTGdyUUN3ME2xPU4xOjBzIN88US=> Ml;4V2FPT0WU
MLMA NXGzcJZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XxR2lEPTB;MUmuNFU2PyEQvF2= MX7TRW5ITVJ?
HCC70 M3LzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTF7LkS4PUDPxE1? MYDTRW5ITVJ?
A704 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHSdGNKSzVyPUG5Mlg{ODVizszN NF\rOnFUSU6JRWK=
D-283MED NFrCO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KwTWlEPTB;MkCuOVM{QSEQvF2= NIT5VVlUSU6JRWK=
U031 NFLBc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW5TWM2OD1{MT6xOFg6KM7:TR?= Ml[xV2FPT0WU
HSC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLxTWM2OD1{MT6xPFM2KM7:TR?= MkfyV2FPT0WU
JVM-3 M4m0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ{LkWwOkDPxE1? NXTjcZNjW0GQR1XS
Mewo M{K4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHKTZF7UUN3ME2yNk42ODd|IN88US=> NGTyXoZUSU6JRWK=
YH-13 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLrTWM2OD1{Mj61NVI{KM7:TR?= M3\KPHNCVkeHUh?=
LB1047-RCC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTJ{LkW4O|kh|ryP NVrGUY55W0GQR1XS
HCC2157 M3nPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XZSWlEPTB;MkKuPFA2PCEQvF2= MULTRW5ITVJ?
SNU-449 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ{Lki3OFgh|ryP NF\4WVZUSU6JRWK=
Ramos-2G6-4C10 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDEOFZKSzVyPUKyMlk3KM7:TR?= NGTrS29USU6JRWK=
CHL-1 NHHzN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTJ|LkeyPVIh|ryP MY\TRW5ITVJ?
SK-MEL-30 M2X4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ2LkS2OlIh|ryP NFHidppUSU6JRWK=
PANC-08-13 NWLkTmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ3LkC5N|gh|ryP Mn70V2FPT0WU
QIMR-WIL NVPabVFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy5RZZKSzVyPUK1MlE5PThizszN NFjNUFdUSU6JRWK=
BFTC-905 NWLGdYNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTVeHFyUUN3ME2yOU42QTR2IN88US=> MoLEV2FPT0WU
GI-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H1UWlEPTB;MkWuO|A2PSEQvF2= NULxXWJWW0GQR1XS
MDA-MB-415 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTkTWM2OD1{Nj61NFM{KM7:TR?= MnjLV2FPT0WU
GT3TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTJ4LkWzOFIh|ryP M3;LSnNCVkeHUh?=
DEL MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLDfm5KSzVyPUK2Mlg{PTZizszN MWXTRW5ITVJ?
KOSC-2 NFS2O|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DaO2lEPTB;Mk[uPVA4PSEQvF2= NEH5PWhUSU6JRWK=
RVH-421 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj6TWM2OD1{Nz6yPVIyKM7:TR?= NUHuNJJXW0GQR1XS
EW-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\pfWJ5UUN3ME2yO{41OzB6IN88US=> NUL3cYp1W0GQR1XS
639-V NIDqXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ5LkWxNVkh|ryP MlzrV2FPT0WU
A2780 NUjyUFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvKdYdqUUN3ME2yO{43PDFizszN MlzMV2FPT0WU
SW982 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ5LkmwOVIh|ryP M{XjXnNCVkeHUh?=
SW1710 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PvNmlEPTB;MkiuNFk5OSEQvF2= NGPqTItUSU6JRWK=
HCC1569 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:4dIlnUUN3ME2yPE41QDl5IN88US=> MXTTRW5ITVJ?
MV-4-11 NE\JPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF70fWlKSzVyPUK4MlU4OzVizszN NGjlZZJUSU6JRWK=
BHT-101 M4jJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC4TWM2OD1{OD62OVczKM7:TR?= M2LGXHNCVkeHUh?=
Ca9-22 M3fnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny2TWM2OD1{OD63NVQh|ryP NET3Z4ZUSU6JRWK=
HAL-01 M1z1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJ6Lke2NVUh|ryP MYfTRW5ITVJ?
D-263MG M4TNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7iT3FKSzVyPUK5MlM1PCEQvF2= M4LmcnNCVkeHUh?=
NEC8 NUfzfoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzBTWM2OD1{OT61OVQ5KM7:TR?= NVf3R3BsW0GQR1XS
EKVX NY\jVVRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DubGlEPTB;M{GuOVg1PyEQvF2= M3Sy[3NCVkeHUh?=
EM-2 M3[zOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUKwbmw2UUN3ME2zNU43OzB2IN88US=> MnvqV2FPT0WU
MFM-223 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFTWM2OD1|MT64NFk5KM7:TR?= MWjTRW5ITVJ?
SK-PN-DW MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN{LkG0NFYh|ryP NX35Z|A3W0GQR1XS
HuO9 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN{LkWyPFIh|ryP MlfBV2FPT0WU
MHH-PREB-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC3TWM2OD1|Mj62NlM1KM7:TR?= NXXaTFJkW0GQR1XS
OVCAR-4 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN{LkizOlMh|ryP NID2UXlUSU6JRWK=
NCI-H1648 NXjU[5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN{Lki2OVEh|ryP NHjrR5JUSU6JRWK=
MKN1 NVKz[VlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorOTWM2OD1|ND6xNVAyKM7:TR?= MmHGV2FPT0WU
KYSE-450 M3HHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfUTWM2OD1|ND62OFQ1KM7:TR?= MVjTRW5ITVJ?
ES8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPT[lZjUUN3ME2zOE45QTd3IN88US=> MlLaV2FPT0WU
MS-1 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTN2Lkm1OVQh|ryP M1npTnNCVkeHUh?=
HOP-92 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnhTWM2OD1|NT65Nlc4KM7:TR?= NYXHOo5lW0GQR1XS
SKG-IIIa MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzUe3dUUUN3ME2zOk4zPTZzIN88US=> MVfTRW5ITVJ?
TE-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M333dmlEPTB;M{[uOVI1OyEQvF2= NFnyRmpUSU6JRWK=
SK-NEP-1 NIT6WYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\KTWM2OD1|Nz62O|Q1KM7:TR?= MXjTRW5ITVJ?
DB NEmyZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TyeWlEPTB;M{euPVE5PSEQvF2= NELwZWJUSU6JRWK=
IA-LM NYnhW2pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN6LkCyN|kh|ryP MVHTRW5ITVJ?
COLO-829 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;IdGlEPTB;M{iuOFE2QSEQvF2= MVPTRW5ITVJ?
TGBC11TKB NX3ZSJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHNY5NUUN3ME2zPU4yPDB6IN88US=> NY\NSldkW0GQR1XS
CAL-51 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS2TFRrUUN3ME20NE4xPjF{IN88US=> NUixe5ExW0GQR1XS
NCI-H2228 NIq3bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPBZmJKSzVyPUSwMlM3PjJizszN MlvlV2FPT0WU
C32 NXHRXG5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRyLkSwNlQh|ryP M1PlZnNCVkeHUh?=
KU-19-19 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRyLke2PFMh|ryP M163ZnNCVkeHUh?=
KNS-62 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfJTWM2OD12MD64N|gyKM7:TR?= M4\pVHNCVkeHUh?=
FADU NGDGXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTjNmxKSzVyPUSxMlI2ODJizszN NF[0UllUSU6JRWK=
CAL-33 NVzqOmppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDRXpRKSzVyPUSyMlY4PDlizszN NYfzOYlrW0GQR1XS
CHP-134 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K1XmlEPTB;NEKuPFQ6PiEQvF2= NH7xcnFUSU6JRWK=
HDLM-2 M4Txe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTR{LkmwPFQh|ryP NWTVfXVNW0GQR1XS
NBsusSR MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTR|LkC3NlUh|ryP M3\IZ3NCVkeHUh?=
SW954 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPLc|dKSzVyPUSzMlExPTNizszN NFPodnRUSU6JRWK=
HCC1806 NWDVcVZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHXfmxKSzVyPUSzMlQyOSEQvF2= MojwV2FPT0WU
VMRC-RCZ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTR|LkS1PFYh|ryP M1OzeXNCVkeHUh?=
A549 NILhdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfvTWM2OD12Mz65N|Eh|ryP NVfpRm9vW0GQR1XS
NKM-1 NX3qPVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR|Lkm1OVgh|ryP NFPRPJZUSU6JRWK=
DMS-273 MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR2Lke1Olch|ryP NVP0dXRKW0GQR1XS
TYK-nu Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[xTWM2OD12NT6xNlM1KM7:TR?= Mn;3V2FPT0WU
KALS-1 NEj5eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvXTWM2OD12NT6xOFYh|ryP NVXrV|BXW0GQR1XS
A101D M4XubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qyR2lEPTB;NEWuOFQ2PiEQvF2= MnzTV2FPT0WU
G-361 NGrPRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;VeGlEPTB;NE[uNlE{QCEQvF2= M3ThdnNCVkeHUh?=
KARPAS-299 NE\aXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O4dWlEPTB;NE[uN|UyPiEQvF2= MU\TRW5ITVJ?
RS4-11 NGHpV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\IO3ZtUUN3ME20Ok42PDJizszN M17pSXNCVkeHUh?=
HT-1376 NF70bHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LZZmlEPTB;NE[uO|QzPiEQvF2= NITJUmZUSU6JRWK=
SK-N-AS NEOxS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTR4Lke4NlIh|ryP Mn\JV2FPT0WU
MG-63 NV;6OXo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ntfWlEPTB;NE[uPVA{PiEQvF2= M3jJfnNCVkeHUh?=
EPLC-272H MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrkTWM2OD12Nj65OVA{KM7:TR?= MlfXV2FPT0WU
BALL-1 NG\Le5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3RW2lNUUN3ME20O{45OzJizszN MXLTRW5ITVJ?
LCLC-97TM1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H5TGlEPTB;NEiuNlAzKM7:TR?= MX3TRW5ITVJ?
HO-1-N-1 M{jEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTR6Lkm2O|Yh|ryP NFHtUIVUSU6JRWK=
MFE-280 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu5[oJKSzVyPUS5MlQ3OTdizszN M1LmZnNCVkeHUh?=
NCI-H526 NEDXZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF72SYNKSzVyPUS5MlgyPjNizszN NVvVfVRxW0GQR1XS
D-566MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Rd|k6UUN3ME20PU46ODl4IN88US=> NWXTTmdpW0GQR1XS
BB30-HNC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjVTmNKSzVyPUS5Mlk1QThizszN NGPVNFJUSU6JRWK=
SK-N-DZ NULSUotZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVyLkC0PFEh|ryP MWDTRW5ITVJ?
HepG2  NXP2XYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[2SFExyqEQvF2= MV6yOEBp M4jDN4Jtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NVi2XFRvOjV3MkexNlM>
HepG2  MWXGeY5kfGmxbjDBd5NigQ>? NUW3cop3OTEEoN88US=> MUiyOEBp M1\UbpN2eHC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdnNib3[gRXROKG:wIGPldlE6QDFuIFPob|Ehd25iU3XyN|Q2NCCFaHuyJI9vKFSqck[4MEBidmRiQ3TrNkBwdiCWeYKxOUBqdmS3Y3XkJIJ6KFOFLVnJTVM> M4nv[FI2PTJ5MUKz
KATO III  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnCeIJ6Oi53L{WvO{42KM7:TR?= M2\McGROW09? NF:wfWRmdmijbnPld{B1cGVidH;4bYNqfHlib3[gc4xieGG{aXK= NXfyTGNGOjR6NEG3NVg>
hTCEpi NYHkPXd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;VeFExKM7:TR?= MlG3SG1UVw>? NEPNbpFxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? M{joWlI1OzdyOEO1
MCF10A NVjhV29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:3ZVExKM7:TR?= MWCyOEBp MYDEUXNQ MVjwc5RmdnSrYYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKEeD Mlv6NlQyPTB3OUW=
HL-60  NH;QPFNHfW6ldHnvckBCe3OjeR?= M2\ReFExKM7:TR?= NEPJU2ExNjViaB?= M3vzXmROW09? M{WwWZJm\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJGNpczMEoB?= NUPIXW1uOjN7M{S0NVE>
MCF-7 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;FdWQyNTFyMN88US=> NWPadXp5OjRiaB?= NX76UmNwTkKV NETTcVBqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NX;QflZlOjNzOEWzOFc>
HeLa  NVHnTW8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\pNU0yODEQvF2= NXXSdG9OOjRiaB?= NGDjd3RHSlN? Mlf3bY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? NYTxVmpVOjNzOEWzOFc>
SH-SY5Y NVG0ZmF1TnWwY4Tpc44hSXO|YYm= MlLmNVDDqM7:TdMg Moi2NlQhcA>? MXvpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? NHL0SlMzOjZ{N{K5OC=>
IMR-32 MlXmSpVv[3Srb36gRZN{[Xl? NEjPS5EyOMLizszNxsA> MlrENlQhcA>? M4XGRolvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| NEC5eG8zOjZ{N{K5OC=>
A549 Mm\sSpVv[3Srb36gRZN{[Xl? NV3tdosyOTEEoN88UeKh M1LESVEhcA>? NVvWcHJGe3WycILld5NmeyCQYX7vMWNwNWmwZIXj[YQheDV|IHHjZ5VufWyjdHnvci=> MW[yNlU2QTN{MR?=
T47D  M3W1cWZ2dmO2aX;uJGF{e2G7 NVu0[YU6OjEEoH3N Ml;aNlQhcA>? MlyzSG1UVw>? M2T0RpBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z MVyyNVE1PDhyNR?=
A29 MEF MnTxSpVv[3Srb36gRZN{[Xl? MXqxNOKh|ryPwrC= MoDJNYg> NV7N[4tI[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? NEDz[FQzODB3M{e4NS=>
MDA-MB-453  NIPYSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[1MVQxKM7:TR?= NHS2c|Y4OiCq M2q5[GlEPTBib3[gNVAh|ryP NFnLdFQzODB3M{e4NS=>
PC-3 NFLEepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGezTFk2NTRyIN88US=> NFvLWnQ4OiCq M{DuZ2lEPTBib3[gNVAh|ryP MYeyNFA2Ozd6MR?=

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO and 47.5% PEG300
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID